L'activité cholinergique non neuronale est potentialisée dans la myasthénie grave

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

L'activité cholinergique non neuronale est potentialisée dans la myasthénie grave

Message par Pboulanger Prés. »

:hi:

Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28178923
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Image

Non-neuronal cholinergic activity is potentiated in myasthenia gravis.
Han B1, Zhang C1, Liu S2, Xia Y3, Sun H4, Gong Z5, Simard AR6, Liu Q1,7, Hao J8.
BMC Neurol. 2017 Feb 8;17(1):28. doi: 10.1186/s12883-016-0772-3.


  • BACKGROUND:
    Non-neuronal acetylcholine (ACh) restricts autoimmune responses and
    attenuates inflammation by cholinergic anti-inflammation pathway. To date, the
    implication of ACh in myasthenia gravis (MG) remained unexplored. This study
    aimed to investigate the possible relationship between ACh levels,
    anti-muscle-specific tyrosine kinase (MuSK) antibody titers, main clinical
    features and outcomes of MG patients.


  • METHODS:
    We successfully measured ACh levels in human peripheral blood
    mononuclear cells (PBMCs) from 125 MG patients and 50 matched healthy controls by
    using ultra-performance liquid chromatography-tandem mass spectrometry
    (UPLC-MS/MS). We assessed the quantitative MG (QMG) scores for each patient and
    titered anti-MuSK antibody.


  • RESULTS:
    We found that PBMC-derived ACh level was significantly higher in MG
    patients, especially in patients of class III, IV-V, compared with that in
    controls (0.142 ± 0.108 vs. 0.075 ± 0.014 ng/million cells, p = 0.0003) according
    to the Myasthenia Gravis Foundation of America clinical classification.
    Importantly, we also found that ACh levels were positively correlated with QMG
    scores (r = 0.83, p < 0.0001) and anti-MuSK Ab levels (r = 0.85, p < 0.0001).


  • CONCLUSIONS:
    Our demonstration of elevated ACh levels in PBMCs of MG patients
    foreshadows potential new avenues for MG research and treatment.


Amicalement,
Image
Verrouillé

Retourner vers « 2017 »